Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes
2015-003490-15Phase 3
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS), familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and 1 more, sponsored by Novartis. Primary endpoint: Number of participants without a relapse.
02
Drugs
canakinumab
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)familial cold autoinflammatory syndrome (FCAS)Muckle-Wells syndrome (MWS)neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on 2015-003490-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003490-15.